The FDA has approved Vaxchora, from PaxVax, a vaccine for the prevention of cholera caused by serogroup O1 in adults...
PaxVax has announced that the FDA accepted for filing and review the Biologics License Application (BLA) for Vaxchora, its cholera...
Emergent BioSolutions announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted...
Vaxchora is indicated for active immunisation against disease caused by Vibrio cholerae serogroup O1 in adults and children aged 2 years and older. This vaccine should be used in accordance with official recommendations.
Bavarian Nordic A/S announced that it has entered into an agreement with Emergent BioSolutions Inc. to acquire two marketed travel vaccines, Vivotif for the prevention of typhoid fever and Vaxchora against cholera as well as a Phase III vaccine candidate for the prevention of Chikungunya virus for a total consideration of up to $ 380 million, including $ 270 million in an upfront payment and up to $ 110 million in future conditional milestone payments
PaxVax has announced positive results from a Phase III safety and lot-to-lot consistency trial of its single-dose oral Cholera vaccine...